NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47), Zacks reports. The business had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million.
NewAmsterdam Pharma Trading Up 0.4 %
NASDAQ NAMS traded up $0.09 during trading on Friday, hitting $21.00. The stock had a trading volume of 1,145,893 shares, compared to its average volume of 677,387. The company's 50-day moving average price is $22.55 and its two-hundred day moving average price is $20.32. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29.
Insider Buying and Selling at NewAmsterdam Pharma
In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $25.54, for a total value of $762,266.84. Following the sale, the insider now owns 10,656,172 shares in the company, valued at approximately $272,158,632.88. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 404,927 shares of company stock worth $10,390,787. Corporate insiders own 19.50% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on NAMS. Scotiabank boosted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday. Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Needham & Company LLC decreased their price objective on NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday. Finally, HC Wainwright reiterated a "buy" rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, NewAmsterdam Pharma presently has an average rating of "Buy" and an average target price of $43.80.
View Our Latest Stock Report on NewAmsterdam Pharma
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
See Also
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
